https://www.selleckchem.com/pr....oducts/bibo-3304-tri
722) and single/combination therapy groups (P = 0.574). Two of 59 (3.4%) and 4/66 (6.1%) patients exhibited clinical failure during treatment (P = 0.683) when receiving IET or IIT, respectively. Eight of 51 (15.7%) receiving IET and 6/58 (10.3%) receiving IIT patients (P = 0.568) had recurring symptoms/signs suggestive of a UTI. Recurrence of a UTI occurred 15.5 days (interquartile range, 9.0-19. after the end of treatment. Time to defervescence and clinical failure did not differ between IET/IIT groups. Non-carbape
Like
Comment
Share
